Doctors have long known that finding colorectal cancer early gives patients the best chance of survival. The challenge is that current screening methods are not perfect.
Colonoscopy is highly effective but invasive, while stool tests are easier but not always completed by patients and may miss some cancers. Researchers now believe a new generation of simple blood tests could change this situation.
A scientific review published in Clinica Chimica Acta has examined years of research on liquid biomarkers and concludes that these emerging technologies could reshape the future of colorectal cancer care.
Instead of relying mainly on invasive procedures, doctors may eventually use blood or stool samples to detect cancer, estimate risk, guide treatment, and monitor patients after therapy.
The researchers reviewed studies published from 2010 to 2025 using leading scientific databases. They focused on high-quality research involving new biomarkers linked with colorectal cancer.
Liquid biomarkers are tiny biological signals found in body fluids. They include circulating tumor DNA, called ctDNA, microRNAs, proteins, metabolites, changes in the gut microbiome, and many other molecules.
Cancer cells release some of these substances into the bloodstream or digestive tract long before a tumor causes symptoms. Detecting these signals may allow doctors to identify cancer much earlier than before.
Modern laboratory technologies have greatly improved scientists’ ability to measure these molecules. Powerful genomic and molecular techniques can now detect extremely small amounts of cancer-related material that previously went unnoticed. Researchers believe combining several biomarkers may provide highly accurate screening while reducing false results.
The review explains that colorectal cancer causes nearly two million new cases worldwide each year. Population aging, unhealthy diets, obesity, lack of exercise, and increasing urbanization are expected to push these numbers even higher. Because early-stage disease is often curable, improving screening remains one of the most effective ways to reduce deaths.
Another advantage of liquid biomarkers is patient acceptance. Many people delay colonoscopy because they dislike bowel preparation or feel uncomfortable about the procedure. A simple blood test could encourage many more people to participate in screening programs, allowing doctors to diagnose cancers at an earlier stage.
Researchers also believe biomarkers may support personalized medicine. Different patients have different tumors, and biomarker profiles may help doctors choose the most effective treatment while monitoring whether therapy is working or whether cancer has returned.
Despite the excitement, experts caution that further validation is still needed before these tests replace existing screening programs. Many of the technologies remain under development, and large clinical studies will determine how they should be used alongside current methods.
The review was published in Clinica Chimica Acta.
This review brings together a large body of evidence showing that liquid biomarkers have enormous potential for colorectal cancer care. Although it does not provide new experimental data, its comprehensive analysis suggests the field is moving rapidly toward less invasive, more accurate, and more personalized screening strategies that could ultimately save many lives.
If you care about cancer, please read studies about how to fight cancer with these anti-cancer superfoods ,and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and cancer-fighting foods and recipes.
Source: Clinica Chimica Acta.
